Accelerate Diagnostics, Inc. Stock

Equities

AXDX

US00430H2013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:30:00 2024-04-26 EDT 5-day change 1st Jan Change
0.9301 USD -1.61% Intraday chart for Accelerate Diagnostics, Inc. +8.28% -76.27%
Sales 2024 * 12.17M 16.63M Sales 2025 * 14.48M 19.79M Capitalization 20.15M 27.54M
Net income 2024 * -49M -66.98M Net income 2025 * -44M -60.14M EV / Sales 2024 * 1.66 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.39 x
P/E ratio 2024 *
-0.41 x
P/E ratio 2025 *
-0.48 x
Employees 134
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.89%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.61%
1 week+8.28%
Current month-6.05%
1 month-3.14%
3 months-27.34%
6 months-84.70%
Current year-76.27%
More quotes
1 week
0.86
Extreme 0.86
1.01
1 month
0.73
Extreme 0.73
1.05
Current year
0.73
Extreme 0.73
4.24
1 year
0.73
Extreme 0.73
11.90
3 years
0.73
Extreme 0.73
93.60
5 years
0.73
Extreme 0.73
240.00
10 years
0.73
Extreme 0.73
318.56
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-07-31
Director of Finance/CFO 38 17-08-31
Chief Operating Officer - 22-12-31
Members of the board TitleAgeSince
Director/Board Member 76 12-06-25
Director/Board Member 83 12-06-25
Director/Board Member 71 19-12-01
More insiders
Date Price Change Volume
24-04-26 0.9301 -1.61% 4,924
24-04-25 0.9453 +1.54% 14,119
24-04-24 0.931 -2.00% 12,785
24-04-23 0.95 +7.05% 137,870
24-04-22 0.8874 +3.31% 18,342

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm

More quotes
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9301
Average target price
-
Consensus